A runner at sunrise in the city, surrounded by suggested molecular structures

Research

What can alpha-lipoic acid do? A look at metabolism, inflammation and oxidative stress

16 min read

Alpha-lipoic acid leads a double life: in Germany it is approved as a medicine for diabetic neuropathy, elsewhere it sits freely on the shelf as a food supplement.1,2 Older texts call it thioctic acid. The body makes it itself, and no deficiency is known.1,2

Hardly any substance in this group has been the subject of so many meta-analyses. And for hardly any other do their results diverge so widely. Anyone who wants to know what alpha-lipoic acid can do therefore has to ask 2 questions: how long did the studies run, and whom did they examine?

This article sets out what these studies measured, how robust they are and what EFSA concluded on safety in 2021.

What is alpha-lipoic acid, and where is it found?

Alpha-lipoic acid is a sulphur-containing fatty acid. The body builds it in the mitochondria from octanoic acid, a fatty acid with 8 carbon atoms. There it is firmly bound to proteins and works as a cofactor of several enzyme complexes.1

The best known is pyruvate dehydrogenase. It converts pyruvate into acetyl coenzyme A, an important starting material of the citric acid cycle. Vitamin B1 also works as a cofactor in the same complex.1

In food, too, alpha-lipoic acid occurs in bound form. Kidney, heart and liver contain a lot of it, and among vegetables spinach and broccoli. The amounts are small: around 1-3 µg per gram of dry weight. Food supplements contain 50-600 mg, up to 1,000 times more than the diet can provide.1

Is alpha-lipoic acid an antioxidant?

In the test tube, yes. Alpha-lipoic acid and its reduced form, dihydrolipoic acid, form a redox couple: they can take up and release electrons.3 In laboratory experiments, both scavenge reactive oxygen species and return oxidised vitamin C, coenzyme Q10 and glutathione to their active form. Vitamin E could also be recovered in this way, directly or indirectly.1

Whether the same happens in the body has not been established. The levels of free alpha-lipoic acid that intake reaches in tissues are at least 10 times lower than those of vitamin C or glutathione. In addition, free alpha-lipoic acid leaves the cells again quickly.1

A molecule that scavenges radicals in a test tube does not automatically improve a clinical measurement.

It is exactly at this point that, for alpha-lipoic acid, biochemistry parts company with the studies in humans.

What is the difference between R- and S-alpha-lipoic acid?

Alpha-lipoic acid exists in 2 mirror-image forms. Only the R form is made by the body itself, and it is the form found in food. Most food supplements contain a racemate, that is, R and S forms in equal parts.1,4 The racemate results from chemical manufacturing.3

It does not simply follow that the pure R form is better. In a small study with 500 mg each, only 2 of 6 older men absorbed the R form better than the racemate. Young men even tended to absorb the racemate better.4

Pure R-alpha-lipoic acid is also sensitive to heat and acid. A study in 6 healthy volunteers therefore compared a stabilised form, bound to gamma-cyclodextrin, with unbound R-alpha-lipoic acid. With the stabilised form, the area under the concentration-time curve was around 2.5 times as large. Several of the authors worked for the manufacturer of this complex.5

Is there an authorised health claim for alpha-lipoic acid?

No. In 2010 the European Food Safety Authority (EFSA) assessed proposed claims for alpha-lipoic acid. They included protection of body lipids from oxidative damage, normal cholesterol levels and normal blood sugar levels. EFSA considered none of these relationships established.2,6

None of these statements may therefore appear on products containing alpha-lipoic acid. How this assessment procedure works is explained in the article on EU health claims.

A study result is not an authorised health claim.

What follows are results from studies. Many of them were obtained in people with diabetes, overweight or other pre-existing conditions.

What do studies show on alpha-lipoic acid, blood sugar and insulin?

Here it is worth laying 2 meta-analyses side by side. They reach opposite results.

A dose-response meta-analysis of 28 studies with 1,016 participants found lower values for insulin and HOMA-IR, a measure of insulin resistance. For glucose and for the long-term blood sugar value HbA1c it found no change. The difference in insulin depended on the duration of intake.7

A second evaluation of 41 studies found exactly the reverse. Fasting blood sugar (6.57 mg/dl) and HbA1c (0.35 points) were lower. Insulin and HOMA-IR did not differ. The authors rated only 19 of the 41 studies as methodologically good and 16 as weak.8

Two meta-analyses, opposite findings

Blood sugar and insulin values with alpha-lipoic acid compared with the control group

Mahmoudi-Nezhad 2020 · 28 trials, 1,016 participants

Insulinlower
HOMA-IRmeasure of insulin resistancelower
Fasting blood sugarno difference
HbA1clong-term blood sugarno difference

Rahimlou 2019 · 41 trials, 16 of them methodologically weak

Insulinno difference
HOMA-IRno difference
Fasting blood sugar6.57 mg/dl lowerlower
HbA1c0.35 points lowerlower

Luo 2025 · 11 trials, 704 overweight adults

HOMA-IRno difference
Fasting blood sugarno difference
Sources as in the text: Mahmoudi-Nezhad et al. 2020, Rahimlou et al. 2019, Luo et al. 2025. A measured difference is not an authorised health claim.

The largest evaluation to date, of 63 randomised trials, found slightly lower figures for all 4 values, for example 5.28 mg/dl for fasting blood sugar.9 A meta-analysis limited to overweight adults, by contrast, found no difference in fasting blood sugar and HOMA-IR. It covered 11 studies with 704 people.10

Reading these papers together, one sees small differences that appear or disappear depending on which studies are selected.

What do studies show on markers of inflammation such as CRP?

The picture is more consistent for markers of inflammation. The evaluation of 41 studies found lower values for TNF-α, interleukin-6 and CRP.8 A dose-response meta-analysis of 20 studies with 947 participants reached the same result. It named baseline values as one cause of the differences between studies.11

A meta-analysis of 11 studies on CRP alone shows where the difference arises. Overall, CRP was 0.72 mg/l lower. In the subgroup with a baseline value above 3 mg/l it was 1.02 mg/l, in studies lasting more than 8 weeks 0.99 mg/l. In participants with diabetes, no difference was established.12

Where CRP was already raised, it fell further

How much lower CRP was than in the control group, meta-analysis of 11 trials

All trials551 participants0.72 mg/l
Baseline above 3 mg/lsubgroup1.02 mg/l
Trial duration over 8 weekssubgroup0.99 mg/l
Source: Saboori et al. 2018. In participants with diabetes, no difference was established.

That is a recurring pattern: where little is out of balance, little can be shifted.

What do studies show on blood lipids, blood pressure and body weight?

A meta-analysis of 12 randomised trials found around 10 mg/dl less total cholesterol and around 9 mg/dl less LDL cholesterol. HDL cholesterol showed no difference, triglycerides only in subgroups.13 The larger evaluation of 63 studies saw no difference in LDL and only 3.91 mg/dl in total cholesterol.9

A review on triglycerides relies mainly on animal experiments. From the few studies in humans it concludes that a difference is most likely with markedly raised values.14 In overweight adults, the meta-analysis of 11 studies found no difference in any blood lipid.10 In fatty liver disease, a meta-analysis of 7 studies found no difference in liver values, blood lipids or weight. This held for every amount and duration examined.15

For blood pressure, a meta-analysis of 11 studies with 674 participants found 5.46 mmHg less for the upper and 3.36 mmHg less for the lower value. The authors consider larger studies necessary.16 The evaluation of 63 studies found no difference in blood pressure.9

For body weight, the authors themselves state the finding most soberly. A meta-analysis of 12 studies found 0.69 kg less body weight and a BMI 0.38 points lower than with placebo. Waist circumference did not change. The authors conclude that alpha-lipoic acid hardly appears cost-effective for this purpose.17

What do studies show in diabetic neuropathy?

The best-known use lies outside food supplements: diabetic polyneuropathy, nerve damage in diabetes. Here alpha-lipoic acid is a medicine.1,2 Older meta-analyses saw clear differences. An evaluation of 15 studies with infusions over 2-4 weeks found faster nerve conduction velocities, with mostly weak methods.18 A more recent one on tablets, from 10 studies with 1,242 patients, found better symptom scores but no difference in other measures.19

In 2024 a Cochrane review reached a different result. It included only studies that ran for at least 6 months: 3 trials with a total of 816 participants. In the study with this measure (330 participants), the symptom score after 6 months was only 0.16 points below placebo. The smallest noticeable difference is considered to be 0.97 points. Its conclusion: probably little or no effect on symptoms. All 3 studies had a high risk of bias due to dropouts.20

The longer the trials, the smaller the effect

Meta-analyses on diabetic polyneuropathy

Han 201215 trials, infusion over 2-4 weeks, mostly weak methodseffect measured
Hsieh 202310 trials, tablets, 1,242 patients, symptoms better, other measures notinconsistent
Cochrane 20243 trials of at least 6 months, 816 participants, 0.16 points difference, noticeable would be 0.97little or no effect
Sources as in the text: Han et al. 2012, Hsieh et al. 2023, Baicus et al. 2024. This concerns the treatment of a disease, not healthy people.

Why the results diverge is no mystery. It is a question of inclusion criteria: short infusion studies on one side, long studies on the other. Added to this is a note from the Linus Pauling Institute: many neuropathy studies come from one German research group and were funded by the German manufacturer.1

These findings concern the treatment of a disease and cannot be transferred to healthy people. They show something more general: early positive results often do not withstand stricter testing.

Which amounts have been studied?

The amounts in the studies lie far above what food provides. In the studies in overweight adults they were 300-1,800 mg a day, over 2 weeks to 6 months.10 In neuropathy research they range from 300-600 mg as an infusion to 1,800 mg as tablets.18-20

The meta-analysis on body weight names up to 1,200 mg a day as the range used safely in the studies.17 For the rare insulin autoimmune syndrome, according to EFSA, no safe amount can be given, as the next section shows.21

Food supplements and studies, amounts compared

Alpha-lipoic acid in milligrams per day

Food supplementsup to 1,000 times more than from the diet50-600 mg
Neuropathy, infusionover 2-4 weeks300-600 mg
Studies in overweight adults2 weeks to 6 months300-1,800 mg
Neuropathy, at least 6 monthsCochrane review600-1,800 mg
Used as safe in weight studiesmeta-analysis, 12 trialsup to 1,200 mg
Sources as in the text: Linus Pauling Institute, Han 2012, Luo 2025, Baicus 2024, Namazi 2017. According to EFSA 2021, a dose below which insulin autoimmune syndrome is not expected cannot be determined.

How safe is alpha-lipoic acid?

In the studies, alpha-lipoic acid was mostly well tolerated. The Cochrane review found probably no difference from placebo in dropouts due to adverse effects within 6 months.20 The evaluation of the infusion studies reported no serious adverse events.18

One exception deserves attention. Alpha-lipoic acid carries sulfhydryl groups. Substances with this group can trigger autoantibodies against insulin in predisposed people. The result is insulin autoimmune syndrome (Hirata's disease), with episodes of low blood sugar.21,22

In an evaluation of 294 cases worldwide, alpha-lipoic acid was the most common trigger in people outside Asia.22 In people of European descent, the gene variant HLA-DRB1*04:03 was found most often.22,23

EFSA assessed this in 2021 on behalf of the European Commission. It evaluated 49 case reports; in all of them the syndrome resolved within weeks to months after stopping. Its conclusion: alpha-lipoic acid in foods and food supplements probably increases the risk in people with certain gene variants. These cannot be identified without a genetic test.21

In Europe the syndrome is rare, probably rarer than in Japan with 0.017 cases per 100,000 inhabitants. According to EFSA, an amount below which insulin autoimmune syndrome is not expected cannot be determined from the data. EFSA found no case report for alpha-lipoic acid from ordinary food.21

At the request of a member state, the European Commission has opened a procedure under which substances in foods can be prohibited, restricted or placed under scrutiny. It concerns alpha-lipoic acid in food supplements. The Commission's page lists no decision on it (as of 15 November 2026).24

When should intake be checked beforehand?

Interactions with medicines are possible, for example with blood sugar lowering drugs and with thyroid hormones. Anyone taking insulin or tablets for diabetes should then have their blood sugar monitored closely. The German consumer advice centres advise taking it only after consulting a doctor and with regular laboratory checks.1,2

The same applies in pregnancy and breastfeeding: safety during breastfeeding has not been established.1,2 Alpha-lipoic acid is not suitable for children and adolescents. A toddler was admitted to hospital after swallowing 4 tablets of 600 mg each.1,2

What does it add up to?

Alpha-lipoic acid is one of the most frequently studied substances of its kind. In an evaluation of 884 randomised trials with almost 900,000 participants, it was among the substances with moderate- to high-quality evidence on cardiovascular risk factors.25

A look at the individual findings shows a pattern. The measured differences are small. They appear mainly where baseline values are unfavourable. The most recent meta-analyses in overweight adults and in fatty liver disease found no difference.10,15 Anyone who knows the evidence on coenzyme Q10 will recognise this pattern.

The most honest sentence about alpha-lipoic acid is therefore: it is a well-described building block of metabolism that the body makes itself. It has no authorised health claim, and EFSA knows of no amount without a risk of insulin autoimmune syndrome.1,6,21

Key takeaways

  • The body makes alpha-lipoic acid itself. Bound to enzymes, it works as a cofactor in the mitochondria. Its action as an antioxidant is established in the test tube and open in the body.1
  • Only the R form occurs naturally. Most products contain a racemate. An advantage of the pure R form in absorption has not been shown consistently in studies.1,4
  • There is no authorised health claim. In 2010 EFSA considered none of the proposed claims established.2,6
  • For blood sugar, blood lipids and weight, the measured differences are small and inconsistent. For weight it was around 0.7 kg, for total cholesterol 4-10 mg/dl depending on the evaluation. In overweight and fatty liver disease, recent meta-analyses found no difference.9,10,13,15,17
  • For CRP, the difference appeared mainly with baseline values above 3 mg/l and in studies of more than 8 weeks.12
  • A 2024 Cochrane review of studies lasting at least 6 months found probably little or no effect on neuropathy symptoms. Older analyses of shorter studies had seen more.18-20
  • ⚠️ In people with certain gene variants, alpha-lipoic acid can trigger insulin autoimmune syndrome. According to EFSA, an amount without this risk cannot be determined.21

Sources

  1. Linus Pauling Institute, Oregon State University. Lipoic Acid. Micronutrient Information Center, updated 2018, reviewed 2019, accessed 15 November 2026.
  2. Verbraucherzentrale (German consumer advice centres), Klartext Nahrungsergänzung. Alpha-Liponsäure - eine Fettsäure gegen Diabetes? (in German). Version of 14 August 2026, accessed 15 November 2026.
  3. Shay KP et al. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta, 2009.
  4. Keith DJ et al. Age and gender dependent bioavailability of R- and R,S-α-lipoic acid: a pilot study. Pharmacol Res, 2012.
  5. Ikuta N et al. Bioavailability of an R-α-lipoic acid/γ-cyclodextrin complex in healthy volunteers. Int J Mol Sci, 2016.
  6. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the substantiation of health claims related to alpha lipoic acid and protection of body lipids from oxidative damage, maintenance of normal blood cholesterol concentrations, increased beta-oxidation of fatty acids, maintenance of normal blood glucose concentrations. EFSA Journal 8(2):1474, 2010.
  7. Mahmoudi-Nezhad M et al. An updated systematic review and dose-response meta-analysis of the effects of α-lipoic acid supplementation on glycemic markers in adults. Nutrition, 2020.
  8. Rahimlou M et al. Alpha-lipoic acid (ALA) supplementation effect on glycemic and inflammatory biomarkers: a systematic review and meta-analysis. Clin Nutr ESPEN, 2019.
  9. Mohammadi S et al. Effects of alpha-lipoic acid supplementation on cardiometabolic risk factors: a systematic review and dose-response meta-analysis. Nutr Metab Cardiovasc Dis, 2025.
  10. Luo Y et al. Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis. BMJ Open, 2025.
  11. Vajdi M et al. An updated systematic review and dose-response meta-analysis of the randomized controlled trials on the effects of alpha-lipoic acid supplementation on inflammatory biomarkers. Int J Vitam Nutr Res, 2021.
  12. Saboori S et al. Effects of alpha-lipoic acid supplementation on C-reactive protein level: a systematic review and meta-analysis of randomized controlled clinical trials. Nutr Metab Cardiovasc Dis, 2018.
  13. Haghighatdoost F, Hariri M. Does alpha-lipoic acid affect lipid profile? A meta-analysis and systematic review on randomized controlled trials. Eur J Pharmacol, 2019.
  14. Pashaj A et al. α-Lipoic acid as a triglyceride-lowering nutraceutical. Can J Physiol Pharmacol, 2015.
  15. Li T et al. Effects of alpha-lipoic acid supplementation on patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized clinical trials. BMC Endocr Disord, 2026.
  16. Vajdi M et al. The effects of alpha lipoic acid (ALA) supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Front Cardiovasc Med, 2023.
  17. Namazi N et al. Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clin Nutr, 2017.
  18. Han T et al. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol, 2012.
  19. Hsieh RY et al. Effects of oral alpha-lipoic acid treatment on diabetic polyneuropathy: a meta-analysis and systematic review. Nutrients, 2023.
  20. Baicus C et al. Alpha-lipoic acid for diabetic peripheral neuropathy. Cochrane Database Syst Rev, 2024.
  21. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Scientific opinion on the relationship between intake of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome. EFSA Journal, 2021.
  22. Patel M et al. Management of insulin autoimmune hypoglycaemia: single-centre experience from Western India with systematic review of world literature. Clin Endocrinol (Oxf), 2020.
  23. Yao D et al. HLA alleles associate with insulin autoimmune syndrome. Diabetes Metab Syndr Obes, 2024.
  24. European Commission. Addition of vitamins and minerals - Addition of certain other substances to foods. Accessed 15 November 2026.
  25. An P et al. Micronutrient supplementation to reduce cardiovascular risk. J Am Coll Cardiol, 2022.

ATLAS All-in-One - 35 ingredients, 4 capsules, once a day.